Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC November Update

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Agomelatine (Valdoxan®) has been rejected for the treatment of major depressive episodes. The economic analysis was insufficiently robust to gain approval.

Fentanyl nasal spray (Instanyl®) has been restricted to use in patients who are unsuitable for other short-acting oral opioids (e.g. oral morphine) for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC November Update' on Email Share 'SMC November Update' on Delicious Share 'SMC November Update' on Digg Share 'SMC November Update' on Facebook Share 'SMC November Update' on Google+ Share 'SMC November Update' on reddit Share 'SMC November Update' on StumbleUpon Share 'SMC November Update' on Twitter

atomic-wealth

No Comments to “SMC November Update”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,668 spam comments.

atomic-wealth
fond-illness
summer